Promising Results from ProKidney's Advanced CKD Trial
In a groundbreaking presentation at the American Society of Nephrology Kidney Week 2025, ProKidney Corp. unveiled full results from their Phase 2 REGEN-007 trial. This trial investigated the efficacy of rilparencel, a novel treatment for patients suffering from advanced chronic kidney disease (CKD) and diabetes. The findings highlight not only the treatment's potential but also the importance of addressing a significant health challenge for many individuals facing the threat of kidney failure.
A Look at Study Details and Outcomes
The Phase 2 REGEN-007 trial was a multi-center, open-label study conducted with a randomized two-arm structure, focusing specifically on patients with advanced CKD and diabetes. Participants were assigned to one of two treatment groups, each following different dosing regimens. One group was treated similarly to the ongoing Phase 3 PROACT 1 study, with bilateral injections of rilparencel, while the other explored a new, disease response-triggered dosing regimen.
From the data shared at ASN Kidney Week 2025, the results from patients receiving the standard dosing regime (Group 1) were striking. Notably, there was a 4.6 mL/min/1.73m² (78%) improvement in estimated glomerular filtration rate (eGFR) slope for these patients. Such improvements are not only statistically significant but also clinically meaningful, indicating the efficacy of rilparencel in this patient population.
Safety and Tolerability of Rilparencel
Safety profiles are crucial in any clinical trial, and the REGEN-007 study reported no serious adverse events related to rilparencel. Instead, the overall safety profile aligned with what had been documented in prior studies and was comparable to that of standard kidney biopsy procedures, reinforcing the treatment's promise.
Dr. Arnold Silva, a principal investigator for the study, emphasized, “These latest findings support the continued evaluation of rilparencel. The evidence of stabilization in kidney function and the well-tolerated safety profile are encouraging as we look towards the future of renal therapies.”
Next Steps: The Phase 3 PROACT 1 Study
As the REGEN-007 trial closes, ProKidney is already advancing to the Phase 3 PROACT 1 study. The FDA has recognized eGFR slope as a suitable endpoint for supporting accelerated approval, which could potentially expedite patient access to this promising therapy. Currently, enrollment in this trial has surpassed half of the approximately 360 patients required, with topline results anticipated in the near future.
Rilparencel stands out as the only cell therapy undergoing Phase 3 trials for treating CKD in conjunction with type 2 diabetes, reinforcing ProKidney's commitment to addressing unmet medical needs in this complex patient demographic.
Understanding Chronic Kidney Disease
Chronic Kidney Disease represents a serious health issue, impacting an estimated 37 million adults in the U.S., many of whom remain undiagnosed in early stages. With diabetes as the leading cause of CKD, individuals with both conditions face heightened risks of complications, including cardiovascular events and hospitalization.
ProKidney is dedicated to exploring innovative treatments like rilparencel for individuals diagnosed with Stage 3b/4 CKD and diabetes. Their research focuses on developing therapies that not only slow disease progression but also stabilize kidney function, aiming to defer or eliminate the necessity for dialysis.
About ProKidney Corp.
Founded in 2015, ProKidney is at the forefront of CKD treatment through advancements in cell therapy. Their lead product, rilparencel (also known as REACT), is recognized for its potential promise in preserving kidney function and is undergoing rigorous evaluation through the ongoing Phase 3 studies. The organization’s innovative approach underscores a commitment to delivering effective, regenerative therapy to those in need.
Frequently Asked Questions
What were the main findings of the Phase 2 REGEN-007 trial?
The trial found that rilparencel significantly improved eGFR slopes in patients with advanced CKD and diabetes, indicating potential to slow disease progression.
How is rilparencel administered in the study?
Rilparencel is administered through bilateral kidney injections, with dosing regimens tailored to each patient's needs.
What safety measures were observed during the trial?
No serious adverse events related to rilparencel were reported, and the overall safety profile was comparable to standard procedures.
What is the Phase 3 PROACT 1 trial?
The Phase 3 PROACT 1 trial is designed to further assess rilparencel's effectiveness and safety in preserving kidney function for CKD patients, with potential for accelerated approval.
What makes rilparencel unique in treating CKD?
Rilparencel is the only cell therapy currently in Phase 3 trials for treating CKD alongside type 2 diabetes, which positions it uniquely in the market.
